1.
ACEP Clinical Policy
Use of Intravenous
Tissue Plasminogen
Activator for the
Management of Acute
Ischemic Stroke in the
Emergency Department
Ann Emerg Med. 2015;66:322-333

2.
This clinical policy from the ACEP
is the revision of a clinical policy
approved in 2012 addressing
critical questions in the
evaluation and management of
patients with acute ischemic
stroke.
A writing subcommittee conducted
a systematic review of the
literature to derive evidence-
based recommendations to
answer the following clinical
questions:

3.
Is IV tPA safe and effective
for patients with acute
ischemic stroke if given
within 3 hours of
symptom onset?

4.
Is IV tPA safe and effective
for patients with acute
ischemic stroke treated
between 3 to 4.5 hours
after symptom onset?

5.
The 2012 IV tPA clinical policy
recommendation to “offer” tPA to patients
presenting with acute ischemic stroke
within 3 hours of symptom onset was
consistent with AHA guidelines.
Unfortunately, the committee’s intent in
using the term “offer” may not have
conveyed the importance of having a
discussion with the patient or family about
the potential benefits and harms of IV tPA;
therefore, we have expanded on this
concept with recommendations addressing
shared decision making.

6.
Classes of Evidence to
Recommendation Levels
Level A recommendations
Generally accepted principles for patient care that
reflect a high degree of clinical certainty
Level B recommendations
Recommendations for patient care that may
identify a particular strategy or range of strategies
that reflect moderate clinical certainty
Level C recommendations
Recommendations for patient care that are based
on evidence from Class of Evidence III studies or,
in the absence of any adequate published
literature, based on expert consensus

7.
This policy is not intended to be a
complete manual on the evaluation
and management of patients with
acute ischemic stroke but rather a
focused examination of critical issues
that have particular relevance to the
current practice of emergency
medicine.

8.
This clinical policy is not intended to
represent a legal standard of care for
emergency physicians.
Recommendations offered in this policy
are not intended to represent the only
diagnostic or management options
available to the emergency physician.
ACEP recognizes the importance of the
individual physician’s judgment and
patient preferences.

9.
Scope of Application
This guideline is intended for physicians
working in EDs
Inclusion Criteria
This guideline is intended for adult patients
aged 18 years and older presenting to the
ED with acute ischemic stroke.
Exclusion Criteria
This guideline is not intended to be used
for pediatric or pregnant patients.

10.
Critical
Questions

11.
Is IV tPA safe and effective
for patients with acute
ischemic stroke if given
within 3 hours of
symptom onset?

12.
Level B recommendations
With a goal to improve functional
outcomes, IV tPA should be offered
and may be given to selected
patients with acute ischemic stroke
within 3 hours after symptom onset
at institutions where systems are in
place to safely administer the
medication.
The increased risk of symptomatic ICH
should be considered when deciding
whether to administer IV tPA to
patients with acute ischemic stroke.

13.
Level C recommendations
When feasible, shared decision
making between the patient
(and/or his or her surrogate)
and a member of the health
care team should include a
discussion of potential benefits
and harms prior to the decision
whether to administer IV tPA for
acute ischemic stroke.

14.
NINDS Criteria NEJM. 1995;333:1581-1587.
Inclusion:
• Acute ischemic stroke with
clearly defined time of onset
(who could be treated <3
hours of symptom onset)
• Measurable deficit on the
NIHSS
• Baseline brain CT scan that
showed no evidence of
hemorrhage
Exclusion:
• Another stroke or serious head injury within the
preceding 3 months
• Major surgery within prior 14 days
• History of ICH
• SBP>185 mmHg or DBP >100 mmHg
• Rapidly improving or minor symptoms
• Symptoms suggestive of SAH
• GI or GU hemorrhage within the previous 21 days
• Arterial puncture at a non-compressible site within
the previous 7 days
• Seizure at onset of stroke
• Use of anticoagulation:
– patients receiving heparin within the 48 hours
preceding the onset of stroke who have an
elevated PTT
– patients with a PT >15 seconds (or INR >1.6)
– patients with a platelet count <100,000
• Glucose level of <50 mg/dL or >400 mg/dL

15.
• Part 1: N=291 (144 tPA); part 2: N=333 (168
(tPA).
• No significant difference between tPA (47%)
and placebo (30%) groups in percentages of
patients with neurologic improvement at 24 h;
at 3 mo the global odds for a favorable
outcome in the tPA group was 1.7 (95% CI
1.2 to 2.6) times the odds in the placebo
group
• Symptomatic ICH <36 h of stroke onset 6% in
tPA and 1% in placebo group (P=.001).
• 3-mo mortality 17% in the tPA group and 21%
in the placebo group (P=.30)

16.
Is IV tPA safe and effective
for patients with acute
ischemic stroke treated
between 3 to 4.5 hours
after symptom onset?

17.
Level B recommendations
Despite the known risk of sICH and
the variability in the degree of
benefit in functional outcomes, IV
tPA may be offered and may be
given to carefully selected
patients with acute ischemic
stroke within 3 to 4.5 hours after
symptom onset at institutions
where systems are in place to
safely administer the medication.

18.
Level C recommendations
When feasible, shared decision
making between the patient
(and/or his or her surrogate) and a
member of the health care team
should include a discussion of
potential benefits and harms prior
to the decision whether to
administer IV tPA for acute
ischemic stroke.

19.
ECASS III Criteria NEJM. 2008;359:1317-1329.
Inclusion:
• Acute ischemic stroke with a
clearly defined time of onset
(who could be treated
between 3 to 4.5 hours from
symptom onset)
• Age 18-80 years
• Stroke symptoms present for
at least 30 minutes without
significant improvement prior
to treatment
• Baseline brain imaging that
showed no evidence of ICH
Exclusion:
Same as NINDS plus the
following additional
criteria:
• Age >80 years
• Severe stroke (NIHSS score
>25) or by appropriate
imaging techniques (defined
as >1/3 of the MCA territory)
• Combination of previous
stroke and DM
• Any oral anticoagulant use
(regardless of INR or PT)

20.
Potential Benefits
and Harms of
Implementing the
Recommendations

21.
Is intravenous tissue
plasminogen activator
safe and effective for
patients with acute
ischemic stroke if given
within 3 hours of
symptom onset?

22.
Potential Benefit of Implementing
the Recommendations
Administration of IV tPA within 3
hours of stroke symptom onset
increases the probability of better
long-term functional outcome
(NNT=8; 95% CI 4 to 31 when
based on data from the Class I
NINDS trial part 2).

23.
Potential Harm of Implementing
the Recommendations
Administration of IV tPA within 3
hours of stroke symptom onset
increases the risk of early sICH
(NNH=17; 95% CI 12 to 34 when
based on data from the Class I
NINDS trial part 2).

24.
Is IV tPA safe and effective
for patients with acute
ischemic stroke treated
between 3 to 4.5 hours
after symptom onset?

25.
Potential Benefit of Implementing
the Recommendations
Administration of IV tPA for patients
with ischemic stroke within 3 to
4.5 hours of stroke symptom
onset may increase the probability
of better long-term functional
outcome (NNT=14; 95% CI 7 to
244 when based on data from the
Class II ECASS III trial).

26.
Potential Harm of Implementing
the Recommendations
Administration of IV tPA for patients
with ischemic stroke within 3 to
4.5 hours of stroke symptom
onset increases the risk of early
sICH (NNH=23; 95% CI 13 to 78
when based on data from the
Class II ECASS III trial).

27.
Question